<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG2>
<DESCRIPTION>Risk of hypoglycemia or hyperglycemia:

decrease or increase of the need for repaglinde due to decrease or increase of the secretion of endogenous glucagon.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen self-monitoring of blood glucose, and adjust the dosage of the repaglinide if needed during the treatment with the somatostatin analog</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of more than double of the concentrations of the repaglinide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering agent during the treatment with the clarithromycin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLOPIDOGREL" rxcui="32968">
<ATC code="B01AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of repaglinide by the clopidogrel, with risk of increase of undesirable effects</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of repaglinide, due to inhibition of its hepatic metabolism by the deferasirox</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, strict clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of severe hypoglycemia, even coma, due to large increase of the plasma concentrations of repaglinide by the gemfibrozil</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these medications together cannot be avoided, strict clinical and biological monitoring.</COMMENT>
</INTERACTION>
</INTERACTIONS>
